STOCK TITAN

LIFECORE BIOMEDICAL, INC. \DE\ Amended Major Shareholder Report

Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13D/A

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





514766104

(CUSIP Number)
Aron R. English, 22NW, LP
590 1st Avenue S, Unit C1
Seattle, WA, 98104
(206) 227-3078

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
06/30/2026

(Date of Event Which Requires Filing of This Statement)


If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).




schemaVersion:


SCHEDULE 13D




Comment for Type of Reporting Person:
Including 2,711,218 Shares issuable upon the conversion of certain shares of Series A Preferred Stock that are convertible within 60 days of the date hereof pursuant to the terms and conditions of the Certificate of Designations, Preferences and Rights of Series A Convertible Preferred Stock of the Issuer. Percentage is based upon 40,220,625 Shares outstanding, consisting of (i) 37,509,407 shares of Common Stock as of April 29, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 6, 2026, plus (ii) 2,711,218 Shares issuable upon the conversion of certain shares of Series A Preferred Stock.


SCHEDULE 13D




Comment for Type of Reporting Person:
Including 2,711,218 Shares issuable upon the conversion of certain shares of Series A Preferred Stock that are convertible within 60 days of the date hereof pursuant to the terms and conditions of the Certificate of Designations, Preferences and Rights of Series A Convertible Preferred Stock of the Issuer. Percentage is based upon 40,220,625 Shares outstanding, consisting of (i) 37,509,407 shares of Common Stock as of April 29, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 6, 2026, plus (ii) 2,711,218 Shares issuable upon the conversion of certain shares of Series A Preferred Stock.


SCHEDULE 13D




Comment for Type of Reporting Person:
Including 2,711,218 Shares issuable upon the conversion of certain shares of Series A Preferred Stock that are convertible within 60 days of the date hereof pursuant to the terms and conditions of the Certificate of Designations, Preferences and Rights of Series A Convertible Preferred Stock of the Issuer. Percentage is based upon 40,220,625 Shares outstanding, consisting of (i) 37,509,407 shares of Common Stock as of April 29, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 6, 2026, plus (ii) 2,711,218 Shares issuable upon the conversion of certain shares of Series A Preferred Stock.


SCHEDULE 13D




Comment for Type of Reporting Person:
Including 2,711,218 Shares issuable upon the conversion of certain shares of Series A Preferred Stock that are convertible within 60 days of the date hereof pursuant to the terms and conditions of the Certificate of Designations, Preferences and Rights of Series A Convertible Preferred Stock of the Issuer. Percentage is based upon 40,220,625 Shares outstanding, consisting of (i) 37,509,407 shares of Common Stock as of April 29, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 6, 2026, plus (ii) 2,711,218 Shares issuable upon the conversion of certain shares of Series A Preferred Stock.


SCHEDULE 13D




Comment for Type of Reporting Person:
Including 2,711,218 Shares issuable upon the conversion of certain shares of Series A Preferred Stock that are convertible within 60 days of the date hereof pursuant to the terms and conditions of the Certificate of Designations, Preferences and Rights of Series A Convertible Preferred Stock of the Issuer. Percentage is based upon 40,220,625 Shares outstanding, consisting of (i) 37,509,407 shares of Common Stock as of April 29, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 6, 2026, plus (ii) 2,711,218 Shares issuable upon the conversion of certain shares of Series A Preferred Stock.


SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D


22NW Fund, LP
Signature:/s/ Aron R. English
Name/Title:Manager
Date:07/02/2026
22NW, LP
Signature:/s/ Aron R. English
Name/Title:President and Sole Shareholder
Date:07/02/2026
22NW Fund GP, LLC
Signature:/s/ Aron R. English
Name/Title:Manager
Date:07/02/2026
22NW GP, Inc.
Signature:/s/ Aron R. English
Name/Title:President and Sole Shareholder
Date:07/02/2026
Aron R. English
Signature:/s/ Aron R. English
Name/Title:Individually and as attorney-in-fact for Nathaniel Calloway
Date:07/02/2026
Bryson O. Hirai-Hadley
Signature:/s/ Bryson O. Hirai-Hadley
Name/Title:Bryson O. Hirai-Hadley
Date:07/02/2026
Nathaniel Calloway
Signature:/s/ Aron R. English
Name/Title:As attorney-in-fact for Nathaniel Calloway
Date:07/02/2026

Keep reading